Research highlight: bis-MPA dendrimers evaluated for delivery of anti-cancer drug doxorubicin
As recently published in Biomacromolecules , researchers CQM at Universidade de Madeira report their evaluation of generation 4 and 5 bis-MPA dendrimers as drug delivery vehicles for anti-cancer drug doxorubicin (DOX), as well as the cytotoxicity of the dendrimers toward healthy human cell lines. The authors report that both hydroxyl and partially amine functionalized dendrimers were cytocompatible, with the dendrimers not affecting the cell viability of lines tested independent of the chemical